Видео ютуба по тегу Trial: Secombit

Updates on the SECOMBIT trial
Updates on the SECOMBIT trial
A subgroup analysis of the SECOMBIT trial
A subgroup analysis of the SECOMBIT trial
Brain metastases and survival evaluation in the SECOMBIT trial
Brain metastases and survival evaluation in the SECOMBIT trial
Combination therapy for melanoma - open questions and the SECOMBIT trial
Combination therapy for melanoma - open questions and the SECOMBIT trial
SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma
SECOMBIT: sequencing of targeted agents/immunomodulatory Abs in metastatic BRAFV600-mutated melanoma
SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations
SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations
How will future trials refine insights provided by DREAMseq in melanoma?
How will future trials refine insights provided by DREAMseq in melanoma?
Ep 24: SECOMBIT
Ep 24: SECOMBIT
SECOMBIT: 4-year OS and tPFS data and preliminary biomarker analysis
SECOMBIT: 4-year OS and tPFS data and preliminary biomarker analysis
SECOMBIT: treatment sequencing in metastatic melanoma and incidence of brain metastasis
SECOMBIT: treatment sequencing in metastatic melanoma and incidence of brain metastasis
Ep 24: SECOMBIT
Ep 24: SECOMBIT
Melanoma highlights from ESMO 2021
Melanoma highlights from ESMO 2021
Treatment selection for stage III BRAF-mutant melanoma
Treatment selection for stage III BRAF-mutant melanoma
Melanoma highlights from ESMO 2021
Melanoma highlights from ESMO 2021
Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies
Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies
Final results from DREAMseq in BRAFV600-mutant metastatic melanoma
Final results from DREAMseq in BRAFV600-mutant metastatic melanoma
Dr. Long on Nivolumab/Ipilimumab in Patients with Melanoma Brain Metastases
Dr. Long on Nivolumab/Ipilimumab in Patients with Melanoma Brain Metastases
Microbiome Interventions to Overcome Immunotherapy Resistance &Treat Immune-Related Adverse Events
Microbiome Interventions to Overcome Immunotherapy Resistance &Treat Immune-Related Adverse Events
Mechanisms of squamous cell carcinoma after Zelboraf use for melanoma
Mechanisms of squamous cell carcinoma after Zelboraf use for melanoma
BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLC
BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLC
ESMO 2024: Breakthroughs in Melanoma Treatment Regimens
ESMO 2024: Breakthroughs in Melanoma Treatment Regimens
Highlights for skin cancer at ESMO 2021
Highlights for skin cancer at ESMO 2021
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber
Анализы крови на препараты, влияющие на В-клетки (Окревус, Ритуксимаб, Кесимпта, Бриумви)
Анализы крови на препараты, влияющие на В-клетки (Окревус, Ритуксимаб, Кесимпта, Бриумви)